Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. ISPC
ISPC logo

ISPC Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
0.250
Open
0.250
VWAP
0.24
Vol
304.29K
Mkt Cap
2.35M
Low
0.233
Amount
73.39K
EV/EBITDA(TTM)
--
Total Shares
9.77M
EV
-437.71K
EV/OCF(TTM)
--
P/S(TTM)
0.21
iSpecimen Inc. is a technology-driven company. The Company addresses a critical challenge, which focuses on connecting life science researchers who need human biofluids, tissues, and living cells (biospecimens) for their research. The Company’s iSpecimen Marketplace platform is designed to solve this problem and transform the biospecimen procurement process to accelerate medical discovery. Its technology consolidates the biospecimen buying experience in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia, and government institutions who need them. In addition to providing the technology platform to connect researchers and healthcare providers, the Company handles all marketing, sales, contracting, and compliance functions across both sides of the marketplace. The iSpecimen Marketplace technology comprises four functional areas: search, workflow, data and administrative, compliance and reporting.
Show More

Events Timeline

(ET)
2026-01-20
06:10:00
iSpecimen Files to Sell 101M Shares of Common Stock
select
2025-12-30 (ET)
2025-12-30
18:30:00
iSpecimen Shares Rise 36.9% After $5.5M Private Placement Announcement
select
2025-12-30
14:50:00
iSpecimen Enters $5.5M Securities Purchase Agreement with Investors
select
2025-07-24 (ET)
2025-07-24
08:41:24
iSpecimen prices 5.7M shares at 70c in underwritten public offering
select
2024-11-07 (ET)
2024-11-07
06:49:54
iSpecimen releases cancer biospecimen offering
select
2024-11-07
06:10:18
iSpecimen reports Q3 EPS ($2.10) vs ($4.66) last year
select
2024-10-18 (ET)
2024-10-18
17:27:44
iSpecimen files to sell 1.22M shares of common stock
select
2024-09-26 (ET)
2024-09-26
07:33:06
iSpecimen secures $1M loan, appoints three board members
select
2024-09-11 (ET)
2024-09-11
16:34:31
iSpecimen announces 1-for-20 reverse stock split
select

News

Benzinga
9.5
02-06Benzinga
Roblox Reports Quarterly Earnings Exceeding Expectations
  • Quarterly Losses in Line: Roblox reported a quarterly loss of $0.45 per share, aligning with analyst expectations, which indicates stability in financial management despite ongoing challenges.
  • Revenue Beats Expectations: The quarterly revenue reached $2.22 billion, surpassing the analyst consensus estimate of $2.05 billion and significantly up from $1.36 billion in the same period last year, showcasing the company's success in user growth and monetization.
  • Stock Price Surge: Roblox shares jumped 14.3% to $69.24 in pre-market trading, reflecting a positive market reaction to the earnings report, which may attract more investor interest.
  • Market Dynamics Impact: The release of this earnings report could influence the stock performance of other related companies, particularly in the gaming and tech sectors, demonstrating market confidence in the industry.
NASDAQ.COM
7.5
01-05NASDAQ.COM
Insilico Medicine Partners with Servier for $888 Million Oncology R&D Collaboration
  • Significant Collaboration Value: Insilico Medicine's multi-year R&D partnership with independent pharmaceutical company Servier is valued at up to $888 million, aimed at leveraging AI-driven drug discovery platforms alongside global expertise in cancer drug development to advance innovative oncology therapies.
  • Upfront Funding Support: Under the agreement, Insilico is set to receive up to $32 million in upfront and near-term R&D payments, which will provide financial backing for its proprietary AI technologies to identify and advance potential drug candidates.
  • Clinical Validation and Commercialization: Servier will share R&D costs and, upon successful identification of promising candidates, will lead clinical validation, regulatory interactions, and worldwide commercialization, further solidifying Insilico's leadership in AI-driven oncology drug discovery.
  • Enhanced R&D Efficiency: By harnessing advanced AI and automation technologies, Insilico has significantly accelerated preclinical drug development timelines, nominating 20 preclinical candidates between 2021 and 2024, achieving this within just 12 to 18 months, thus setting a new benchmark for efficiency in drug R&D.
Benzinga
5.0
2025-12-31Benzinga
Vanda Pharmaceuticals' NEREUS Receives FDA Approval, Shares Surge 17.5%
  • FDA Approval: Vanda Pharmaceuticals' NEREUS (tradipitant) has received FDA approval for the prevention of motion-induced vomiting in adults, marking a significant advancement in the company's neuropharmaceutical portfolio and is expected to drive future sales growth.
  • Stock Surge: Following the FDA approval announcement, Vanda's shares jumped 17.5% to $8.26 in pre-market trading, reflecting strong market confidence in the new drug's potential and likely attracting increased investor interest.
  • Market Outlook: The approval of NEREUS not only opens new market opportunities for Vanda Pharmaceuticals but also enhances its market share in the competitive antiemetic drug sector, strengthening the company's long-term profitability prospects.
  • Investor Confidence: This FDA approval boosts investor expectations for Vanda's future performance, potentially prompting more institutional investors to reassess their portfolios, further driving the stock price upward.
Benzinga
9.5
2025-12-31Benzinga
Anghami Inc. Reports 97% Year-over-Year Revenue Surge in Latest Earnings
  • Revenue Surge: Anghami Inc. reported a remarkable 97% year-over-year revenue increase in its latest earnings, showcasing its strong growth potential in the Arab music streaming market and further solidifying its market position.
  • Stock Price Rally: Following the positive earnings report, Anghami Inc.'s stock surged 56% in pre-market trading, reflecting investor optimism about the company's future prospects and potentially attracting more investor interest.
  • Enhanced Market Competitiveness: With significant revenue growth, Anghami not only strengthens its competitive edge in the fiercely contested streaming industry but also positions itself for sustainable long-term growth by expanding its user base.
  • Strategic Investment Opportunity: The positive performance in this earnings report presents new investment opportunities for potential investors, especially against the backdrop of rising digital content consumption in the Arab region, making Anghami's market outlook increasingly promising.
Benzinga
8.5
2025-12-31Benzinga
iSpecimen Inc. Secures $5.5M Financing, Shares Surge 42.36%
  • Successful Financing: iSpecimen announced a $5.5 million private placement with accredited investors, planning to issue 6,875 shares of Series C Convertible Preferred Stock at $800 per share, expected to close on Wednesday, thereby providing essential funding to enhance marketing and operations.
  • Capital Allocation Plans: The proceeds from this financing will be allocated towards marketing initiatives, working capital needs, and general corporate purposes, demonstrating the company's strategic intent to enhance market competitiveness and operational efficiency.
  • Stock Price Volatility: Following the financing announcement, iSpecimen's shares surged 42.36% in after-hours trading to $0.42, despite a staggering 88.88% decline over the past 12 months, reflecting market optimism about its short-term prospects.
  • Market Performance Analysis: Although the stock has rebounded in the short term, iSpecimen's Relative Strength Index (RSI) stands at 24.97, indicating long-term weakness, with a market capitalization of only $2.90 million, suggesting that the company requires strong catalysts to improve its overall trend.
Globenewswire
8.5
2025-12-30Globenewswire
iSpecimen Secures $5.5 Million in Funding to Expand Market Reach
  • Funding Agreement Reached: iSpecimen has entered into a securities purchase agreement with accredited investors for approximately $5.5 million, reflecting market confidence in its biospecimen marketplace.
  • Preferred Stock Issuance: The company will issue 6,875 shares of newly designated Series C Convertible Preferred Stock at $800 per share, which is expected to strengthen its capital structure and support future growth.
  • Clear Use of Proceeds: The net proceeds from the offering will be allocated for marketing, working capital, and general corporate purposes, indicating the company's strategic intent to expand its operations and enhance market competitiveness.
  • Compliance Assurance: This financing will be conducted via a private placement under Section 4(a)(2) of the Securities Act of 1933, ensuring compliance and protecting investor interests.

Valuation Metrics

The current forward P/E ratio for iSpecimen Inc (ISPC.O) is -0.02, compared to its 5-year average forward P/E of -13.48. For a more detailed relative valuation and DCF analysis to assess iSpecimen Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-13.48
Current PE
-0.02
Overvalued PE
41.35
Undervalued PE
-68.31

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.48
Current EV/EBITDA
-0.04
Overvalued EV/EBITDA
2.24
Undervalued EV/EBITDA
-5.19

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.44
Current PS
0.23
Overvalued PS
3.24
Undervalued PS
-0.37

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

tech stocks under 200 ma
Intellectia · 256 candidates
Market Cap: <= 200.00MSector: Financial Technology (Fintech) & Infrastructure, Software & IT Services, Technology, Technology EquipmentList Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
BOXL logo
BOXL
Boxlight Corp
1.27M
SOBR logo
SOBR
Sobr Safe Inc
1.38M
SMTK logo
SMTK
SmartKem Inc
1.93M
MYSZ logo
MYSZ
My Size Inc
2.08M
CCTG logo
CCTG
CCSC Technology International Holdings Ltd
2.17M
WBUY logo
WBUY
Webuy Global Ltd
2.22M

Whales Holding ISPC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is iSpecimen Inc (ISPC) stock price today?

The current price of ISPC is 0.24 USD — it has decreased -4

What is iSpecimen Inc (ISPC)'s business?

iSpecimen Inc. is a technology-driven company. The Company addresses a critical challenge, which focuses on connecting life science researchers who need human biofluids, tissues, and living cells (biospecimens) for their research. The Company’s iSpecimen Marketplace platform is designed to solve this problem and transform the biospecimen procurement process to accelerate medical discovery. Its technology consolidates the biospecimen buying experience in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia, and government institutions who need them. In addition to providing the technology platform to connect researchers and healthcare providers, the Company handles all marketing, sales, contracting, and compliance functions across both sides of the marketplace. The iSpecimen Marketplace technology comprises four functional areas: search, workflow, data and administrative, compliance and reporting.

What is the price predicton of ISPC Stock?

Wall Street analysts forecast ISPC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ISPC is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is iSpecimen Inc (ISPC)'s revenue for the last quarter?

iSpecimen Inc revenue for the last quarter amounts to 106.59K USD, decreased -96.00

What is iSpecimen Inc (ISPC)'s earnings per share (EPS) for the last quarter?

iSpecimen Inc. EPS for the last quarter amounts to -0.48 USD, decreased -77.14

How many employees does iSpecimen Inc (ISPC). have?

iSpecimen Inc (ISPC) has 24 emplpoyees as of March 12 2026.

What is iSpecimen Inc (ISPC) market cap?

Today ISPC has the market capitalization of 2.35M USD.